Clinical Trial Update: NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating NC410 with FOLFIRINOX, with or without nivolumab and ipilimumab, for untreated metastatic pancreatic cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• FOLFIRINOX
• NC410
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Pancreatic Cancer | Phase 2 | Status: RECRUITING